Lesa Sroufe & Co
- SEC CIK
- 0001492162
- Latest filing
- Jul 22, 2026
AMGN holding history
Amgen Inc in every 13F filed by Lesa Sroufe & Co, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AMGN overviewAll 13F holders of AMGNFull Q2 2026 holdings
- Shares (Q2 2026)
- 8,490
- Value
- $3.07M
- % of portfolio
- 2.2%
- Quarters held
- 20
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 8,490 | $3.07M | 2.2% | 00.0% | Unchanged | Holders |
| Q1 2026 | 8,490 | $2.99M | 2.0% | 00.0% | Unchanged | Holders |
| Q4 2025 | 8,490 | $2.78M | 2.1% | 00.0% | Unchanged | Holders |
| Q3 2025 | 8,490 | $2.40M | 1.9% | 00.0% | Unchanged | Holders |
| Q2 2025 | 8,490 | $2.37M | 2.2% | 00.0% | Unchanged | Holders |
| Q1 2025 | 8,490 | $2.65M | 2.6% | – | No prior filing | Holders |
| Q4 2024 | – | – | – | – | Not filed | Holders |
| Q3 2024 | 8,490 | $2.74M | 2.6% | 00.0% | Unchanged | Holders |
| Q2 2024 | 8,490 | $2.65M | 2.6% | 00.0% | Unchanged | Holders |
| Q1 2024 | 8,490 | $2.41M | 2.3% | 00.0% | Unchanged | Holders |
| Q4 2023 | 8,490 | $2.44M | 2.5% | 00.0% | Unchanged | Holders |
| Q3 2023 | 8,490 | $2.28M | 2.4% | 00.0% | Unchanged | Holders |
| Q2 2023 | 8,490 | $1.89M | 2.0% | 00.0% | Unchanged | Holders |
| Q1 2023 | 8,490 | $2.05M | 2.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 8,490 | $2.23M | 2.5% | 00.0% | Unchanged | Holders |
| Q3 2022 | 8,490 | $1.91M | 2.3% | – | No prior filing | Holders |
| Q2 2022 | – | – | – | – | Not filed | Holders |
| Q1 2022 | 8,490 | $1.93M | 1.9% | 00.0% | Unchanged | Holders |
| Q4 2021 | 8,490 | $1.91M | 1.9% | 00.0% | Unchanged | Holders |
| Q3 2021 | 8,490 | $1.80M | 1.9% | 00.0% | Unchanged | Holders |
| Q2 2021 | 8,490 | $2.07M | 2.1% | 00.0% | Unchanged | Holders |
| Q1 2021 | 8,490 | $2.11M | 2.3% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.